Germany's Merck KGaA has agreed to acquire U.S. lab-tools provider Bio-Techne Corporation for $73 per share in an all-cash deal valued at $11.3 billion. The acquisition bolsters Merck's next-generation life sciences portfolio, brings significant multi-omics synergies, and delivers a 36% premium to Bio-Techne's monthly average trading price.
The multi-billion-dollar deal creates a major life sciences entity to accelerate advanced multi-omics and next-generation biology workflows.
DARMSTADT, Germany & MINNEAPOLIS, Minn. — Germany’s Merck KGaA announced on Thursday, June 25, 2026, that it has entered into a definitive agreement to acquire U.S.-based lab-tools provider Bio-Techne Corporation for $73 per share in an all-cash transaction. The landmark deal values Bio-Techne at a total enterprise value of approximately $11.3 billion (€9.9 billion). The strategic acquisition marks a significant consolidation within the global life sciences sector, aimed at blending Merck's global manufacturing footprint with Bio-Techne's robust capabilities in multi-omics, analytical instruments, and biological consumables.
Transaction Specifics and Market Impact
According to a joint regulatory disclosure released on June 25, 2026, the agreed purchase price of $73 per share represents a 24% premium over Bio-Techne's closing price on Wednesday and a 36% premium relative to the stock's one-month volume-weighted average trading price. Bio-Techne's stock responded dynamically to the announcement, surging 23.9% in pre-market trading to approach the offer price.
Merck stated that it intends to fund the multi-billion-dollar buyout using a combination of existing cash reserves and the issuance of new debt. The company emphasized that the transaction structure will allow it to retain its strong investment-grade credit rating. The deal is expected to be immediately accretive to Merck's sales growth and pre-exception EBITDA margins upon closing, with earnings per share (EPS) forecast to become accretive by the third year.
Strategic Rationale and Synergy Targets
The transaction underscores a push by Merck’s newly appointed Chief Executive Officer, Kai Beckmann, to bolster the German conglomerate's high-growth business segments. By incorporating Minneapolis-based Bio-Techne into its Life Science business sector, Merck significantly expands its reach in next-generation biology, bioprocessing, and advanced therapeutics. Bio-Techne brings a highly specialized portfolio, including its proprietary Ella analytical platform and its recent expansion into cell therapy workflows via its planned integration of Wilson Wolf.
Financial filings indicate that Merck projects annual cost synergies of approximately €140 million, which are anticipated to be fully realized by the third year following the official closure of the deal. Furthermore, the combined entity expects to tap into extensive cross-selling opportunities by matching Bio-Techne's cutting-edge life science reagents with Merck's substantial global omnichannel sales network.
Corporate Background and Investor Context
The acquisition follows a period of mounting external pressure on Bio-Techne's corporate leadership. Activist investor Ananym Capital Management recently sent an official dispatch to Bio-Techne’s board of directors, advocating for a formal strategic review and an eventual sale to a larger global competitor. Ananym argued that a corporate combination would unlock far greater value for shareholders than Bio-Techne could generate as an independent, standalone enterprise.
The deal comes at a time when global biopharma tools suppliers are navigating fluctuating research and development budgets from biotech clients. For Merck, this acquisition stands out as its largest transaction since its prior major life science expansions, signaling a definitive return to large-scale mergers and acquisitions to defend its position against global rivals like Thermo Fisher Scientific and Danaher.
Official Sources Section
Details of this transaction are based on formal joint corporate announcements issued by Merck KGaA and regulatory filings submitted by Bio-Techne Corporation to the U.S. Securities and Exchange Commission (SEC), alongside ad-hoc financial disclosures mandated under Article 17 of the EU Market Abuse Regulation.
Quote Section
"According to officials from both corporations, the combined portfolio will offer customers an integrated workflow solution traversing the entire scientific journey, effectively bridging the gap between early-stage academic research and commercialized bioprocessing."
Why It Matters
The acquisition holds broad structural implications for the global scientific and investment communities. For pharmaceutical companies and clinical researchers, the merger consolidates essential laboratory workflows, potentially lowering procurement complexities for multi-omics and cell therapy development. For institutional investors, the deal highlights a resurgence in high-value healthcare sector consolidation driven by strategic acquirers looking to optimize cash reserves amid transitioning corporate leadership.
Key Facts at a Glance
Acquisition Price: Merck KGaA will acquire Bio-Techne for $73 per share in cash.
Total Valuation: The deal values Bio-Techne at an enterprise value of approximately $11.3 billion (€9.9 billion).
Market Premium: The $73 offer is a 36% premium over Bio-Techne's one-month average trading price.
Financial Synergies: Estimated annual cost synergies of €140 million are expected by year three.
Financing: Funded through a blend of existing cash and new debt while preserving Merck's investment-grade rating.
FAQ Section
When is the Merck and Bio-Techne deal expected to close?
The transaction is subject to customary closing conditions, including required regulatory authorizations and the formal approval of Bio-Techne shareholders. A definitive closing timeline will be specified following regulatory reviews.
How will this transaction affect current Bio-Techne shareholders?
Upon successful regulatory and shareholder approval, current Bio-Techne shareholders will receive $73 in cash for each share of common stock they hold.
Why did Merck decide to buy Bio-Techne?
Merck entered the agreement to scale its life science division, adding advanced tools in multi-omics, next-generation biology, and cell therapy to its global commercial distribution framework.
Source: Merck KGaA Investor Relations, Bio-Techne Corporation SEC Filings, EQS Group News Service.
